|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular & Cellular Proteomics 4:1155-1166, 2005.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ABSTRACT |
|---|
|
|
|---|
1, bound with moderate affinities (10100 µM) to a group of non-conventional peptides. Of particular interest, the PLC-
1 SH3 domain was found to associate with SLP-76 through at least three distinct sites, two of which bore a novel KKPP motif and the other contained the classic PXXP sequence. Intriguingly mutation of critical residues for the three sites not only affected binding of SLP-76 to the PLC-
1 SH3 domain but also to the Grb2 C-terminal SH3 domain, indicating that the binding sites in SLP-76 for the two SH3 domains are overlapped. Our studies suggest that the SH3 domain is an inherently promiscuous interaction module capable of binding to peptides that may or may not contain a PXXP motif. Furthermore the identification of numerous non-conventional SH3-binding peptides in SLP-76 implies that the global ligand pool for SH3 domains in a mammalian proteome may be significantly greater than previously acknowledged.
Extensive biochemical and biophysical analysis of numerous SH3 domains and their complexes in the past decade have provided tremendous insights into their specificity and structural basis of ligand recognition (4, 9). Nevertheless with the recent identification of a number of non-conventional SH3 domain-mediated interactions (1013), it has become increasingly clear that our understanding of this important class of interaction module is far from being complete. A growing body of literature suggests that SH3 domains possess specificity beyond the recognition of the conventional class I and II ligands. For example, the SH3 domains from the tyrosine kinase substrate Eps8 and related proteins bind selectively to sequences containing a PXXDY motif (14). The SH3 domains of Fyn and Fyn-binding protein, Fyb/SLAP130, engage a site in the Src kinase associated protein of 55 kDa (SKAP55) with a consensus sequence RKXXYXXY that is devoid of proline (15). The SH3 domains of signal transducing adaptor molecule 1 (STAM1) and STAM2/EAST/Hbp, a family of proteins involved in cytokine signaling and receptor-mediated endocytosis and exocytosis, bind to a PX(V/I)(D/N)RXXKP motif conserved in associated molecule with the SH3 domain of STAM (AMSH) and the deubiquitinating enzyme UBPY (16). Similar sequences harboring an (R/K)XX(K/R) core motif have also been identified in a group of proteins that play important roles in tyrosine kinase and/or immunoreceptor signaling, including Gab1/Gab2, BLNK (B cell linker), Fyb, hematopoietic progenitor kinase 1 (HPK1), and SLP-76 (10, 11, 1719). In vitro and in vivo experimental data showed that the conserved (R/K)XX(K/R) motif in these proteins was responsible for their respective interactions with the C-terminal SH3 (SH3-C) domains of Grb2 and/or Gads (10, 11, 19). Collectively these observations suggest that SH3 domains possess a rather broad specificity. It should be noted that, although the affinity of an SH3 domain for its cognate ligand is usually weak with a typical dissociation constant in the 1100 µM range, the Gads C-terminal SH3 domain was shown to bind an RSTK-containing peptide derived from SLP-76 with submicromolar affinity (10, 11).
Proline-rich regions (PRRs), like SH3 domains, are highly prevalent in eukaryotic proteomes (2). The length of a PRR varies from a few to hundreds of amino acids. A PRR often nucleates interactions with proteins containing the SH3 domain or other proline recognition modules such as the WW, GYF, and enabled VAsp homology (EVH) domains (9, 20). This is epitomized by SLP-76, a multidomain protein that plays an essential role in T cell development and activation (21). In addition to three N-terminal tyrosine phosphorylation sites and a C-terminal SH2 domain, SLP-76 contains a proline-rich region that spans more than 250 residues (Fig. 1). The SLP-76 PRR displays some features common to many known proline-rich sequences. For instance, it is very long and covers a significant part of the SLP-76 polypeptide chain. Moreover apart from a high content of Pro residues (
25%), it contains numerous positively charged residues (34 in total, underlined in Fig. 1). Curiously despite the possibility that many potential SH3 domain-binding sites may be embedded in its sequence, the SLP-76 PRR has not been extensively investigated. To date, only two proteins, namely Gads and PLC-
1, have been shown to associate with SLP-76 through direct physical interactions with its PRR (10, 22, 23).
|
1 SH3 domain. Although the measured affinities were generally above 10 µM, they were comparable to that between an SH3 domain and a conventional, PXXP-containing ligand. Furthermore the PLC-
1 SH3 domain was found to engage at least three distinct sites in SLP-76 of which two contained a novel KKPP motif. Ala-scanning and permutation peptide arrays were used to define critical residues for binding in these sequences, and the physiological relevance of these binding sites was investigated using SLP-76 variants bearing mutations of one or more critical residues. | EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
1, and the p85 subunit of PI3K were amplified by PCR and subcloned into the pGEX4T2 vector. The letters N, M, and C in the parentheses denote the N-terminal, middle, and C-terminal SH3 domain, respectively. Proteins were expressed in Escherichia coli as GST fusions and affinity-purified on glutathione-Sepharose beads (Amersham Biosciences) according to the manufacturers protocols. Bound proteins were eluted in 20 mM glutathione, 50 mM Tris, pH 8.0, 100 mM NaCl and were concentrated in 20 mM phosphate buffer, pH 7.0, 100 mM NaCl prior to use in binding studies.
Synthesis of Peptide Spot Arrays on Derivatized Cellulose Membranes and Probing of the Peptide Arrays by SH3 Domains
The SLP-76 proline-rich region (residues 162412) was represented by a series of undecamer peptides. These peptides, 120 in total, were generated by "walking," from the N to the C terminus, through the sequence of the PRR with a window of 11 amino acids and a frameshift of two amino acids between consecutive peptides. These peptides were assembled in an array format on a functionalized cellulose membrane by multiple peptide synthesis (28) using the Auto-Spot Robot ASP 222 (Abimed).
The peptide array membrane was moistened sequentially with ethanol and water before being probed by purified GST-SH3 proteins. Specifically the peptide array membrane was washed three times in TBS-T buffer containing 20 mM Tris-HCl, 140 mM NaCl, 0.1% (v/v) Triton X-100, pH 7.6, and blocked in 5% BSA in TBS-T for 1 h at room temperature. Approximately 1.0 µM total GST fusion SH3 domains were added directly to the blocking solution and incubated with the membrane for 1 h at room temperature. The membrane was then washed three times in TBS-T and once in TBS before an anti-GST monoclonal antibody was added. After a 30-min incubation with the antibody, the array membrane was washed extensively in TBS and developed using either the enhanced chemifluorescence (ECF) or ECL Western blot kit (Amersham Biosciences). The binding signals on the peptide array were captured by and analyzed on a Fluor-S Multi-Imager (Bio-Rad).
Peptide Synthesis and Fluorescence Polarization Measurements
Individual peptides were synthesized at 0.1-mmol scale on a 431A Peptide Synthesizer (Applied Biosystems) using standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry. For fluorescein labeling, an appropriate amount of 5-(and-6)-carboxyfluorescein succinimidyl ester (Molecular Probes) was added to a peptide resin, and the coupling reaction was allowed to proceed for 1 h at room temperature. Upon cleavage of a peptide from the resin using trifluoroacetic acid, the fluorescein-labeled peptide was separated from the unlabeled peptide by HPLC on a Luna C18 column (Phenomonex). Identities of the peptides were confirmed by mass spectrometry. Fluorescent polarization measurements were performed as described previously (28). A varied amount of a purified GST-SH3 protein was titrated to a fluorescent peptide solution in 20 mM PBS, pH 7.0, 100 mM NaCl. The SH3 domain-peptide mixtures were allowed to incubate in the dark for 30 min prior to fluorescent anisotropy measurements at 20 °C. Binding curves were generated by fitting the isothermal binding data to a hyperbola nonlinear regression model using Prism 3.0 (GraphPad Software, Inc., San Diego, CA), which also produced the corresponding dissociation constants (Kd).
Cell Culture, GST Pull-down, Co-immunoprecipitation, and Western Blot
Human embryonic kidney (HEK) 293 cells (from ATCC) were cultured in Dulbeccos modified Eagles medium supplemented with 10% (v/v) fetal bovine serum, 10 units/ml penicillin, and 10 µg/ml streptomycin. Cells were transiently transfected with expressing plasmids (pFLAG) containing either the wild-type or a mutant slp-76 by means of Lipofectamine (Invitrogen). All SLP-76 mutants used were generated using the QuikChange site-directed mutagenesis strategy (Stratagene) except for mutant R237A, which was a kind gift from Jane McGlade. The same strategy was used also for the creation of the Grb2 SH3-C domain mutants E171A and E174A in the pGEX4T2 vector. Cells were harvested 60 h post-transfection in a buffer containing 50 mM Hepes, pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EDTA, 10 mM Na2P2O7, 10 mM NaF and supplemented with protease inhibitors (1 µM pepstatin A, 2 µM E64, 1 µM bestatin, 10 µM leupeptin, 1 µg/ml aprotinin, 100 µM PMSF; Sigma). For pull-down studies, aliquots of cleared HEK 293 cell lysate each containing 100 mg of total proteins were mixed with either GST, a GST-SH3 domain, or a GST-SH3 mutant immobilized on glutathione-agarose beads for 2 h at 4 °C. Bound proteins were collected by centrifugation and resolved by 12% SDS-PAGE. Protein bands were blotted onto PVDF membranes (Roche Diagnostics) and Western blotted using an anti-FLAG antibody (Santa Cruz Biotechnology, Inc.).
For co-immunoprecipitation of Grb2 and SLP-76, FLAG-tagged SLP-76 and Myc-tagged Grb2 were expressed either singularly or in combination in HEK 293 cells. The corresponding cell lysate was immunoprecipitated using an anti-FLAG or an anti-Myc antibody and Western blotted using both antibodies.
| RESULTS |
|---|
|
|
|---|
1), adaptor or docking proteins (i.e. Gads, Grb2, NCK, and Crk), and a structural protein (i.e. spectrin). Of the 15 SH3 domains examined, eight displayed significant affinities for SLP-76. The C-terminal SH3 domain of Gads and the PLC-
1 SH3 domain exhibited strong binding to SLP-76 as expected. Interestingly the SH3 domains from several proteins that have not been shown previously to interact directly with SLP-76, such as Src, Fyn, NCK, and p85 (PI3K), also demonstrated robust binding to SLP-76. These data indicate that the SLP-76 PRR can accommodate multiple interactions mediated by different SH3 domains. Although the physiological relevance of novel interactions identified here awaits further investigation, it is worth noting that PI3K, Grb2, and NCK are components of a multiprotein complex in T cell signaling, referred to as the signalosome, that is nucleated by SLP-76 and the linker of activated T cells (LAT) (29).
Conventional and Novel SH3 Domain-binding Sequences Identified through "Peptide Walking" through the Pro-rich Region of SLP-76
To identify the potential SH3-binding sites in the SLP-76 PRR, we represented the PRR as an array of overlapping peptides using the SPOT technology of multiple peptide synthesis (28). Specifically a series of undecamer peptides was assembled in an array format on a nitrocellulose membrane by walking through the entire PRR sequence (residues 161412) with a sliding window of two amino acids (Fig. 3A). A total of 120 peptide spots were generated to cover the entire PRR. These spots were numbered sequentially from 97 to 216 because the PRR array was originally synthesized as a part of a larger peptide array. Amino acid sequences corresponding to the arrayed peptides are listed in Supplemental Table S1.
|
|
|
To validate results obtained from the peptide array screening and to determine the binding affinities of individual SH3 domains for non-conventional peptides in solution, we selectively synthesized six peptides, namely p102, p127, p132, p142, p177, and p187, based on sequence novelty and strength of the corresponding binding signals on arrays probed using both individual and mixed SH3 domains (Table II). The peptides corresponded to those displayed on the array (Fig. 3B) but were extended by two residues on both the N and C termini to eliminate possible end effect. Consequently each peptide in Table 2 represents three consecutive spots on the PRR array. For example, peptide p102 encompassed spots 101103, peptide p127 included spots 126128, and so on. A fluorescein label was attached to the N terminus of each peptide to facilitate binding assays using fluorescent polarization. Because peptides p127, p132, and p142 exhibited binding to the SH3-C domains of Grb2, Gads, and/or NCK, we examined the interactions of the six peptides with these SH3 domains by fluorescence polarization. The spectrin SH3 domain, which showed no binding in the GST pull-down assay (Fig. 2), was used as a control (Fig. 4). Results from peptide-SH3 domain binding in solution are displayed in Fig. 4 and summarized in Table II. In agreement with previous reports, the Gads-binding peptide, p132, bound both the Gads and Grb2 SH3-C domains with high affinities (10, 11). These SH3 domains, however, differ in specificity for the remaining peptides. Thus, although the Grb2 SH3-C domain displayed weak to moderate affinities for peptides p102, p127, and p142, the Gads SH3 domain did not exhibit significant binding to the same peptides (Table II), suggesting that the interaction between Grb2 and SLP-76 involved more than one site. Binding of peptide p102 to the Grb2 SH3-C domain was surprising because it did not produce a positive signal in the peptide array screen (Supplemental Fig. S1). This discrepancy suggests that correlation between peptide binding on the membrane and in solution was imperfect.
|
|
The PLC-
1 SH3 Domain Recognizes Multiple Sites in the SLP-76 PRR
Upon the activation of the T cell receptor, SLP-76 associates with PLC-
1. This interaction involves the PRR of the former and the SH3 domain of the latter. Two regions of the SLP-76 PRR are thought to directly mediate its interaction with PLC-
1: the P-1 region that encompasses residues 157223 and the P-2 region between residues 245 and 314 (23). Deletion of either region significantly compromised the ability of T cell receptor in signaling through PLC-
1 (23). To map the precise binding sites for the PLC-
1 SH3 domain, we synthesized a subarray targeting specifically the P-1 and P-2 regions of SLP-76. Peptides in the subarray were made two residues longer than those in the whole PRR array such that each peptide now contained 13 amino acids. Probing the subarray by purified PLC-
1 SH3 domain led to the identification of three major binding sites: one was located in the P-1 region (designated p1a), and the other two resided in the P-2 region (named p2a and p2b, respectively) (Fig. 5A). The PLC-
1 SH3 domain is known to bind to class II ligand with the preferred sequence PPVPPRP (5). Although peptide p1a has the characteristics of a class II ligand, neither peptide p2a nor p2b contains a similar sequence. Interestingly peptide p2a overlaps with peptide p142 that was shown earlier to bind the Grb2 and the NCK SH3-C domains (Table II).
|
1 SH3 domain, an alanine-scanning array was synthesized for peptide p1a, and a permutation array was assembled for peptide p2a. These arrays were then probed with purified PLC-
1 SH3 domains. As shown in Fig. 5B, substituting the C-terminal Arg residue or those in the PVPP motif led to either complete or partial loss of binding for peptide p1a. In contrast, replacement of Pro residues outside the PVPP core motif by Ala had no significant effect. Interestingly substituting an Ala for the first Lys or the last Gln residue augmented binding, suggesting that peptide hydrophobicity played a role in binding to PLC-
1 SH3 domain (Fig. 5B).
Notwithstanding the above observations, permutation analysis on peptide p2a revealed that the positively charged Lys residues were the most important determinants in binding to the PLC-
1 SH3 domain. In particular, the pair of lysines located near the N terminus of the peptide could only be replaced by either another basic or an aromatic residue (Fig. 5C). In comparison, a proline in the peptide could be changed to any amino acid, except Asp and Glu, without incurring significant loss of affinity. Acidic residues appeared to be disfavored at all positions of the peptide except being immediately before the C-terminal lysine as in the native sequence. Even at this position, a negative charge was not necessary for binding because replacement of the Asp residue in the native sequence by any other amino acid either maintained or enhanced the affinity of the peptide (Fig. 5C). Collectively these data indicate that positively charged residues play a pivotal role in mediating the interaction between peptide p2a and the PLC-
1 SH3 domain. The dual Lys residues in peptide p2b were found to play a similar role in binding the PLC-
1 SH3 (data not shown).
Peptide p2b resembles a class II ligand in that it contains a PPVP core motif. However, it lacks an Arg residue that is normally C-terminal to the core. To determine the importance of the PPVP motif and the minimal sequence required for binding the PLC-
1 SH3 domain, we synthesized a series of truncated versions of peptide p2b by progressive deletion of residues from either the N or the C terminus of the peptide (Fig. 6). Truncation of the C-terminal two residues of the PPVP motif did not affect binding. However, a decrease in affinity was evident when the dual Pro residues were omitted (Fig. 6). A complete loss of binding was observed when the dual Lys residues were taken out of the peptide, signifying the importance of the KK pair, instead of the PPVP motif, in binding the PLC-
1 SH3 domain. In contrast, deleting residues N-terminal to the central proline had a negligible effect on binding. Taken together, these data suggest that the minimal sequence for p2b binding to the PLC-
1 SH3 domain is PGKKPP (Fig. 6). A similar study conducted on peptide p2a resulted in a minimal sequence of KKPP for binding (Fig. 6). Thus, despite the apparent discrepancies in sequence for the two peptides, they share a common motif, KKPP, that is important for binding to the PLC-
1 SH3 domain.
|
1 SH3 Domain to Both Conventional and Novel Peptide Sequences
1 SH3 domain, peptides p-1a, p-2a, and p-2b were individually synthesized and purified for binding studies in solution. These peptides were made two residues longer than they were on the array to facilitate fluorescein labeling (Table III). A series of p-2a analogues were also generated to investigate specifically the roles of basic, acidic, and aromatic residues in binding. Moreover to assess the contribution of the KKPP motif to SH3 binding, a GKKPP minipeptide was synthesized. Finally a peptide identified as a PLC-
1 SH3 domain ligand in a phage display library screen (5) was synthesized and used as a positive control in subsequent binding studies by fluorescent polarization.
|
1 SH3 domain assumed saturable patterns with a similar Kd value of
11 µM. It is remarkable that both peptides were capable of binding to the PLC-
1 SH3 domain with a similar affinity despite drastic differences in their primary structures. Peptide p-2b, on the other hand, displayed a significantly lower affinity than did either peptide p-1a or p-2a despite both peptides p-2b and p-2a containing a KKPP motif. Although peptide array studies indicated that this motif was indispensable for binding, the minipeptide GKKPP failed to bind the PLC-
1 SH3 domain in solution. This is analogous to a class I or II ligand in which residues flanking the core sequence play an important part in governing the affinity and specificity of the ligand (30). Using phage-displayed libraries, Sparks et al. (5) found that the PLC-
1 SH3 domain selected for the motif PPVPPRPXXT. A 16-residue peptide, p-ctrl, containing this extended motif bound with high affinity (3 µM) to the PLC-
1 SH3 domain (Fig. 7 and Table III). The relatively low affinities displayed by the SLP-76 peptides suggest that they are not optimized for binding to the PLC-
1 SH3 domain.
|
50 and 70% reduction in affinity (Table III). These results reinforced our earlier observation that the pair of Lys residues was important for binding. However, replacing the Asp residue in peptide p2a by an Ala did not have a significant effect. In comparison, changing the Gly residue to a Tyr slightly increased the affinity of peptide p-2a(G/Y) (Table III). Except for peptide p-2a(D/A), these in-solution binding data agreed in principle with those obtained from the peptide array studies (Fig. 5C).
Role of Distinct Sites in SLP-76 Binding to the PLC-
1 SH3 Domain
To address the question of whether the PLC-
1 SH3-binding sites identified from the peptide studies function in the context of full-length proteins, we generated a series of SLP-76 variants containing mutations, at each site, of residues found to be important for binding (Fig. 8A). For instance, the C-terminal Arg residue was shown to be indispensable for binding of peptide p-1a to the PLC-
1 SH3 domain. The corresponding residue, Arg-192 in SLP-76, was mutated to a Gln to create mutant R192Q or M-1a. It was expected that this mutation would maintain the hydrophilic character of the Arg side chain but eliminate its positive charges. Similarly mutant M-2a contained mutations of Lys-259 and Lys-260 in SLP-76 that corresponded to the double Lys in the KKPP motif of peptide p-2a. The equivalent pair of Lys residues of peptide p-2b was mutated to two Gln residues in mutant M-2b. In addition to these single site mutants, double and triple site mutants were also created to ascertain whether different sites act in an independent or cooperative manner in binding. To assess their relative affinities for the PLC-
1 SH3 domain, these mutants were expressed in HEK 293 cells and subjected to pull-down assays using purified GST-PLC-
1 SH3 domain. As shown in Fig. 8B, although the GST-PLC-
1 SH3 domain was able to pull down the wild-type SLP-76, its ability to precipitate mutants M-1a and M-2a was either abolished or drastically reduced. In contrast, most of mutant M-2b in the lysate was brought down by the GST-SH3 beads, indicating that the p2b site played a relatively minor role in SLP-76-PLC-
1 SH3 domain interaction. Intriguingly although the triple mutant M-1a/2a/2b was completely incapable of binding to the SH3 domain as expected, the double mutants M-1a/2a, M-2a/2b, and M-1a/2b exhibited weak to moderate affinities for the PLC-
1 SH3 domain. This latter result suggests that the three binding sites in SLP-76 may not function independently from one another in binding to the PLC-
1 SH3 domain. Alternatively the conformation of the PRR may be affected differently by the various combinations of mutations.
|
1 and Grb2 SH3-C Domains Overlap in SLP-76
1 SH3 domain, the Grb2 SH3-C domain appeared to engage multiple sites in SLP-76. In addition, peptide p142, which was shown to bind weakly to the Grb2 SH3-C domain, overlaps in sequence with peptide p2a. This suggests that binding sites for the two SH3 domains in SLP-76 may also partially overlap. To explore the role of the various binding sites of the Grb2 SH3-C domain, we used a group of seven SLP-76 mutants in a GST-pull down study (Figs. 8 and 9). Besides the mutants described for the PLC-
1 SH3 domain, two additional mutants, namely M-gb and M-1b, were generated (Fig. 8A). Mutant M-gb or R237A was created in a previous study to investigate the role of the RSTK motif in peptide p132 to Gads SH3-C binding (11). Mutant M-1b or R223E, on the other hand, was generated to probe the importance of the RNHK motif in peptide p127 (Table II).
|
1 SH3 domain also impaired its interaction with the Grb2 SH3-C domain.
Sequence alignment suggests that the C-terminal SH3 domains of Grb2, Gads, and NCK are closely related to the PLC-
1 SH3 domain (Supplemental Fig. S2). One characteristic of this group of SH3 domains is the presence of multiple (at least three) acidic residues in the RT loop (Supplemental Fig. S2). Because a pair of Glu residues present in the RT loop of the Gads SH3-C domain was previously shown to play a pivotal role in binding SLP-76 (11), we predicted that equivalent residues in Grb2 SH3-C would have a similar function. To test this hypothesis, we generated three variants of the Grb2 SH3-C domain that contained mutation(s) of either one or both acidic residues (Glu-171 and Glu-174) in the RT loop. Binding studies using these mutants confirmed the critical importance of the two acidic residues in binding to SLP-76 because mutants with either or both Glu residues changed to an Ala (Fig. 9C) failed to bind SLP-76.
| DISCUSSION |
|---|
|
|
|---|
We used peptide spot array in conjunction with peptide and protein binding assays to identify a group of novel SH3 ligands from the Pro-rich region of SLP-76. Several findings from this small scale proteomic study are worth noting. First, the SLP-76 PRR is capable of supporting a large number of SH3 domain-mediated interactions. Although it is not clear how many of these interactions are physiologically relevant and, if they are, how they are regulated in the cell, our data suggest that it may be necessary to characterize these interactions simultaneously and systematically to achieve a comprehensive understanding of the function of SLP-76. The same argument is likely applicable to other proline-rich regions that harbor multiple binding sites for Pro recognition domains. Second, the majority of potential SH3-binding sites identified in the SLP-76 PRR do not conform to either the class I or II consensus. Rather these sites are rich in basic residues. Therefore, apart from recognizing conventional PXXP motif-containing sequences, SH3 domains are capable of binding to positively charged peptides. Numerous peptides identified in SLP-76 PRR as potential SH3 ligands bear one or more basis motifs such as RXXK, KXXK, and KKPP. Although several SH3 domains, including those from Grb2, Gads, and PLC-
1, bound with moderate affinities to these motifs, it is likely that they are recognized by many more SH3 domains, especially by SH3 domains that contain multiple acidic residues in their RT loops. It is interesting to note, in this regard, that a basic peptide devoid of prolines can confer sufficient affinity to an SH3 domain under physiological conditions. For example, the Bin-1 SH3 domain binds to a basic motif, (K/R)XXXXKX(K/R)(K/R), present in the same molecule through an intramolecular interaction and thereby blocks the binding of the SH3 domain to its physiological target dynamin (37). Third, a single SH3 domain can engage multiple, distinct sites, and a given site may be recognized by more than one SH3 domain. For example, both the Grb2 SH3-C and the PLC-
1 SH3 domains bind to multiple sites in SLP-76, and the two SH3 domains commonly recognize at least one site represented by p142/p2a. Fourth, our studies not only identified the binding sites for known ligands of SLP-76 such as PLC-
1, they also uncovered many potentially interesting interactions. Although the biological significance of these interactions awaits further investigation, direct binding of SLP-76 PRR to the SH3 domains of Grb2, PI3K-p85, and NCK may be of functional relevance as these proteins coexist in a signalosome nucleated by LAT following T cell receptor activation. Moreover both Grb2 and PI3K can associate with LAT through their respective SH2 domains (29). The NCK SH2 domain can also bind to phosphorylated Tyr residues at the N-terminal region of SLP-76 upon its recruitment to LAT by Gads. The array of SH3 domain-mediated interactions observed in the present study may thus cooperate with the SH2 domain the formation of the T cell signalosome.
Compared with the high affinity displayed by the RXXK-containing peptide p132 for the Gads SH3-C domain, most novel peptides identified from the current study exhibited weak or moderate affinities for their receptor SH3 domains. Although it is reasonable to assume that high affinity often translates to high specificity (38), most SH3 domain-mediated, physiological interactions are of moderate affinities. Cellular signal transduction is a dynamic process that requires the formation of a particular signaling complex when the stimulus is on and the dissociation of the complex when the signal is attenuated or switched off. This dictates that most protein-protein interactions occurring in cellular signal transduction be transient. Furthermore the presence of multiple weak to moderate binding sites in a single polypeptide chain for an SH3 domain may be a mechanism used by the cell to regulate SH3-mediated interactions (20). Although the SH3 domain may dissociate quickly from one site, it can be recaptured by a neighboring site. This way, the presence of multiple binding sites effectively increases the local concentration of the SH3 domain and thereby promotes binding. This mechanism of regulation is exploited by the CD2 binding protein 2 (CD2BP2) GYF domain that binds only weakly to a single copy of a Pro-rich motif in CD2. However, when two copies of the same motif are present in a single polypeptide, its affinity for the GYF domain increases by 10-fold (39). It is likely that a similar mechanism underpins the interaction between SLP-76 and PLC-
1 SH3 domain.
In conclusion, we have presented here an effective method by which to map the specificity and interaction partners of SH3 domains. The peptide-walking array approach can be readily expanded to include a larger set of Pro-rich regions and SH3 domains. It may also be adapted to investigate other proline recognition domains. Similar approaches have been developed for the identification of binding partners for the WW domains on a proteome scale (40). Peptide arrays, in conjunction with bioinformatics and other proteomic and genomic strategies, would prove to be a powerful tool for the identification of the global ligand pool for peptide interaction domains.
| FOOTNOTES |
|---|
Published, MCP Papers in Press, May 31, 2005, DOI 10.1074/mcp.M500108-MCP200
1 The abbreviations used are: SH, Src homology; SLP-76, SH2 domain-containing leukocyte protein of 76 kDa; Grb2, growth factor receptor-bound protein 2; PLC, phospholipase C; SH3-C, C-terminal SH3; PRR, proline-rich region; PI3K, phosphatidylinositol 3-kinase; HEK, human embryonic kidney; LAT, linker of activated T cells; ECF, enhanced chemifluorescence. ![]()
* This work was supported in part by grants (to S. S.-C. L.) from the Cancer Research Society, Inc., the National Cancer Institute of Canada, and the Canadian Institute of Health Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ![]()
S The on-line version of this article (available at http://www.mcponline.org) contains supplemental material. ![]()
|| A scientist of the National Cancer Institute of Canada with funds made available by the Canadian Cancer Society. To whom correspondence should be addressed: Dept. of Biochemistry, University of Western Ontario, London, Ontario N6A 5C1, Canada. Tel.: 519-850-2910; Fax: 519-661-3175; E-mail: sli{at}uwo.ca
| REFERENCES |
|---|
|
|
|---|
, Crk, and Grb2.
Proc. Natl. Acad. Sci. U. S. A. 93, 1540
1544
-helical and PPII-helical ligands to a peroxisomal SH3 domain.
Mol. Cell 10, 1007
1017[CrossRef][Medline]
1 (PLC-
1) SH3 domain-binding site in SLP-76 required for T-cell receptor-mediated activation of PLC-
1 and NFAT.
Mol. Cell. Biol. 21, 4208
4218This article has been cited by other articles:
![]() |
X. Ge, Y. Qiu, H. H. Loh, and P.-Y. Law GRIN1 Regulates {micro}-Opioid Receptor Activities by Tethering the Receptor and G Protein in the Lipid Raft J. Biol. Chem., December 25, 2009; 284(52): 36521 - 36534. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Fernando, J. S. Sandoz, W. Ding, Y. de Repentigny, S. Brunette, J. F. Kelly, R. Kothary, and L. A. Megeney Bin1 Src Homology 3 Domain Acts as a Scaffold for Myofiber Sarcomere Assembly J. Biol. Chem., October 2, 2009; 284(40): 27674 - 27686. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Stollar, B. Garcia, P. A. Chong, A. Rath, H. Lin, J. D. Forman-Kay, and A. R. Davidson Structural, Functional, and Bioinformatic Studies Demonstrate the Crucial Role of an Extended Peptide Binding Site for the SH3 Domain of Yeast Abp1p J. Biol. Chem., September 25, 2009; 284(39): 26918 - 26927. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shen, J. Lau, M. Zhu, J. Zou, D. Fuller, Q.-j. Li, and W. Zhang The importance of Src homology 2 domain-containing leukocyte phosphoprotein of 76 kilodaltons sterile-{alpha} motif domain in thymic selection and T-cell activation Blood, July 2, 2009; 114(1): 74 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Beach, R. Gonen, Y. Bogin, I. G. Reischl, and D. Yablonski Dual Role of SLP-76 in Mediating T Cell Receptor-induced Activation of Phospholipase C-{gamma}1 J. Biol. Chem., February 2, 2007; 282(5): 2937 - 2946. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kumar, S. Feske, A. Rao, and R. S. Geha A 10-aa-long sequence in SLP-76 upstream of the Gads binding site is essential for T cell development and function PNAS, December 27, 2005; 102(52): 19063 - 19068. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Madureira, P. Matos, I. Soeiro, L. K. Dixon, J. P. Simas, and E. W.-F. Lam Murine {gamma}-Herpesvirus 68 Latency Protein M2 Binds to Vav Signaling Proteins and Inhibits B-cell Receptor-induced Cell Cycle Arrest and Apoptosis in WEHI-231 B Cells J. Biol. Chem., November 11, 2005; 280(45): 37310 - 37318. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |